Metabolic Health9 min read·Published September 18, 2026

Diabetes Blood Glucose Machines: How to Choose a Meter or CGM

A plain-English guide to glucose meters, CGMs, accuracy, finger pricks, and when to involve your clinician.

Diabetes Blood Glucose Machines: How to Choose a Meter or CGM

A diabetes blood glucose machine usually means either a finger-prick blood glucose meter or a continuous glucose monitor. Meters show a point-in-time blood sugar reading from a drop of blood; CGMs track glucose trends over time. The best choice depends on diabetes type, medications, hypoglycemia risk, cost, insurance, and clinician guidance.

Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.

See if you qualify →

What is a diabetes blood glucose machine?

A diabetes blood glucose machine is usually a home device that helps measure glucose, the sugar your body uses for energy. The FDA describes a blood glucose monitoring device as a handheld meter plus test strips that measure glucose in a small blood sample 1.

Blood glucose meter, glucometer, and CGM: what the terms mean

A blood glucose meter, often called a glucometer, uses a lancet to prick the skin and a test strip to read capillary blood glucose. A continuous glucose monitor, or CGM, uses a small sensor worn on the body to estimate glucose throughout the day and night 2.

What each device actually measures: capillary blood vs interstitial glucose

A meter measures glucose in capillary blood from a fingertip or, for some meters, another approved site. A CGM estimates glucose in interstitial fluid, the fluid around cells, so it can lag behind blood glucose when levels are rising or falling quickly 2.

Why readings are useful but not a diagnosis by themselves

Home readings can help you and your clinician see patterns after meals, activity, medication, or illness. But diabetes mellitus, type 1 diabetes, type 2 diabetes, and prediabetes are diagnosed with clinical history and lab tests such as fasting blood glucose, A1C / HbA1c, or oral glucose testing, not one home reading alone 2. For number ranges, see our guide to normal blood sugar levels.

What quick facts should you know before buying one?

Most glucose meters require a blood sample and a new test strip for each check. CGMs can reduce routine finger pricks, but accuracy still depends on the device, the user, and the situation 1.

  • Meters need test strips, a lancet, and correct technique. Strip cost and insurance coverage often matter as much as the meter price.
  • CGMs can show trend arrows, high and low alerts, time in range, and glucose variability that single finger-stick checks may miss 3.
  • A clinician should help decide what numbers to check, when to check them, and what action plan applies to you 1.
  • Home monitoring is most useful when the data leads to safer treatment decisions, not when it creates anxiety or constant checking.

Who should monitor blood sugar at home?

Home glucose monitoring is most important for people whose treatment decisions depend on current glucose levels, especially people using insulin or medicines that can cause hypoglycemia. It can also help some people with type 2 diabetes or prediabetes understand patterns, when used with clinician guidance 1.

People with diabetes using insulin or medications that can cause low blood sugar

People using insulin may need glucose data to reduce the risk of hypoglycemia, or low blood sugar, and hyperglycemia, or high blood sugar. The FDA notes that patients and clinicians can use home results to decide treatment adjustments and recognize dangerously high or low glucose 1.

People with type 2 diabetes who are adjusting diet, activity, or treatment

For type 2 diabetes, a meter or CGM may help show how meals, walking, sleep, illness, and medications affect glucose. Systematic reviews suggest diabetes monitoring systems can improve some glycemic outcomes for some patients, but results vary by population, device, and study design 4.

When home monitoring is not a substitute for lab tests

A home device does not replace A1C / HbA1c testing, fasting lab glucose, kidney checks, eye exams, or visits with a diabetes clinician. If you are tracking glucose because of weight changes or diabetes risk, our guides to weight loss and diabetes and weight loss for prediabetes explain how clinicians think about the bigger picture.

Which is better for diabetes: a glucose meter or a CGM?

A glucose meter is often enough when you need occasional point-in-time checks. A CGM may add value when trends, overnight lows, alerts, or time-in-range data would change care 3.

FeatureBlood glucose meter / glucometerContinuous glucose monitor / CGM
What it measuresCapillary blood glucose from a blood dropEstimated interstitial glucose from a sensor
Data styleOne number at one momentTrends over hours and days, often with alerts
Finger pricksUsually needed for each checkReduced for many users, but confirmation may still be needed
Best fitOccasional checks, budget limits, backup deviceHypoglycemia risk, insulin use, variable glucose, need for trend data
Trade-offsStrip cost, finger discomfort, missed patterns between checksSensor cost, skin irritation, data overload, insurance rules
Data sharingSome meters store or upload readingsMany CGMs share reports with apps or care teams

When a basic meter may be enough

A basic meter may work well if your clinician wants spot checks, if cost is a major concern, or if you need a backup for a CGM. The FDA suggests considering accuracy, sample size, ease of use, test speed, data storage, strip cost, technical support, and accessibility features when choosing a meter 1.

When CGM may add useful trend and alert information

A CGM may be useful when hypoglycemia risk is high, glucose swings are hard to catch, or overnight patterns matter. A systematic review found CGM can provide information about glucose variability and hypoglycemia that fasting glucose or random capillary checks may miss 3.

Cost, insurance, comfort, and data-sharing tradeoffs

The best device is not always the most advanced one. Ask what your insurance covers, whether you can afford ongoing strips or sensors, whether the device is easy to read, and whether your clinician can review the data.

What makes a glucose meter accurate?

Accuracy can change with the meter, test strips, technique, storage, medical factors, medications, supplements, and the environment. The FDA advises using authorized strips, following device instructions, and avoiding shared meters because blood exposure can spread infection 1.

Device selection checklist

  • Choose an FDA-cleared meter and test strips authorized for sale in the United States.
  • Check whether the strips are affordable and easy to find.
  • Look for features you will actually use: large display, audio readout, lighting, app syncing, memory, or simple buttons.
  • Wash and dry hands before testing unless your device instructions say otherwise.
  • Use strips before the expiration date and store them as directed.
  • Do not share lancing devices or meters with another person.
  • Bring the device or reports to visits so your care team can compare patterns with lab results.

Medical factors and substances that can affect readings

Some readings can be off because of severe dehydration, anemia, extreme hematocrit, high uric acid, altitude, temperature, humidity, or certain substances. The FDA lists possible interference from acetaminophen, vitamin C, and xylose therapies for some devices, so the device instructions matter 1.

Why alternate-site testing may be less reliable when glucose is changing quickly

Some meters allow alternate-site testing, such as the palm or forearm. Those readings may lag when glucose is changing fast, such as after meals, exercise, or insulin, so many clinicians prefer fingertip checks for suspected highs or lows 2.

Can you monitor blood sugar without pricking your finger?

CGMs can reduce routine finger-stick testing for many people, but they do not remove every need for a meter. Some device instructions and clinical situations still call for blood glucose confirmation 2.

How CGMs reduce routine finger-stick testing

CGMs can send glucose estimates to a receiver or phone throughout the day. This can show postprandial glucose after meals, overnight lows, glucose variability, and time in range in a way that a few finger-stick checks cannot 3.

Why some CGM users may still need a meter for confirmation

A meter may still be needed when symptoms do not match the sensor reading, during rapid glucose changes, during sensor warm-up, or when device instructions advise confirmation. Many people with diabetes keep a meter as a backup even when they use a CGM 1.

What over-the-counter glucose biosensors can and cannot do

Some over-the-counter glucose biosensors are marketed for general wellness or for people not using insulin. They may help some users see patterns, but they are not a replacement for diabetes care, prescribed CGM use, or a clinician’s plan for insulin, glucagon, or other glucose-lowering medications.

Why truly non-invasive glucose monitoring remains an evolving area

Truly non-invasive glucose monitoring is still being studied. ClinicalTrials.gov lists research on non-invasive glucose approaches, but a research listing is not the same as proof that a device can replace FDA-authorized meters or CGMs 5.

How do food, walking, and weight changes affect glucose readings?

Glucose readings often change after meals, activity, sleep loss, stress, illness, and weight change. The useful question is not “what is the single worst food?” but “what patterns happen in my body, and what should I do with that information?”

Why carbohydrates can raise post-meal glucose

Carbohydrates break down into glucose, so postprandial glucose often rises after carb-containing meals. Protein, fat, fiber, portion size, timing, medications, and activity can change the size and timing of that rise 9.

How activity can change glucose patterns

Walking and other activity can change glucose patterns by helping muscles use glucose. The effect depends on intensity, timing, fitness, insulin use, and recent food intake, so people at risk for hypoglycemia should follow a clinician’s plan 10.

What personalized nutrition studies suggest

Personalized nutrition research shows that people can have very different glucose responses to the same foods. In a 2015 Cell study, Zeevi and colleagues used continuous glucose data and other inputs to predict individual post-meal responses; a 2021 randomized trial in prediabetes found a postprandial-response-targeting diet improved glycemic control compared with a standard Mediterranean diet approach in that study population 6 7. Individual results vary.

How weight loss can help some people with prediabetes or type 2 diabetes

For some adults with prediabetes, type 2 diabetes, insulin resistance, or metabolic syndrome, weight loss can improve glucose patterns and A1C, but it does not guarantee remission 11. If this is your main concern, our article on metabolic syndrome and weight loss explains why waist size, blood pressure, triglycerides, HDL, and fasting glucose are often reviewed together.

How does blood glucose monitoring fit into weight-loss treatment at Chia?

Chia does not sell blood glucose meters, CGMs, insulin, glucagon, or diabetes-only monitoring programs. We do provide clinician-reviewed weight-loss care for eligible adults, and glucose readings can be useful information to share with your diabetes clinician and, when relevant, your Chia provider.

At Chia, treatment starts with a 100% online health questionnaire. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is never guaranteed. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door.

For weight-loss care, Chia offers compounded semaglutide injection. Semaglutide is the active ingredient in Wegovy, Ozempic, and Rybelsus; FDA labeling describes semaglutide as a GLP-1 receptor agonist 12. Chia’s compounded semaglutide is not FDA-approved, and outcomes data are not established for Chia’s compounded formulation.

Chia also offers compounded tirzepatide tablets and injection. Tirzepatide is the active ingredient in Zepbound and Mounjaro; FDA labeling describes tirzepatide as acting on GIP and GLP-1 receptors, which are incretin hormone pathways 13. Chia’s compounded tirzepatide is not FDA-approved, and outcomes data are not established for Chia’s compounded formulation.

Chia optionForms listed in Chia catalogCurrent starting priceNotes
SemaglutideInjectionPlans currently start at $249/moMicrodosing plans available when clinically appropriate
TirzepatideTablets or injectionTablets currently start at $249/mo; injection currently starts at $299/moMicrodosing plans available when clinically appropriate
Weight + EnergyNAD+ injection plus choice of GLP-1Plans currently start at $309/moFor eligible patients whose provider agrees this protocol fits their goals; compounded medications and this protocol are not FDA-approved

If you already have diabetes, share glucose meter or CGM patterns with the clinician who manages your diabetes, especially if you use insulin or medications that can cause hypoglycemia. Starting, stopping, or changing weight-loss medication may change appetite, food intake, and glucose patterns, so your diabetes care team should know.

3-min quiz

Considering weight-loss care alongside metabolic tracking?

Chia offers clinician-reviewed weight-loss care with semaglutide or tirzepatide when appropriate after a licensed-provider evaluation. A prescription is not guaranteed. Compounded medications are not FDA-approved and are compounded in the US by state-licensed 503A pharmacies.

What should you ask your clinician before buying a glucose meter or CGM?

Before buying a device, ask what decision the data is meant to support. A simple meter may be enough for one person, while another person may need CGM alerts, trend reports, or data sharing.

  1. 1What numbers should I check: fasting blood glucose, before meals, after meals, bedtime, or during symptoms?
  2. 2What readings require urgent care, and what readings should prompt a same-day call?
  3. 3Do any of my medications increase hypoglycemia risk?
  4. 4Should I use a meter, CGM, or both?
  5. 5Which devices and strips are covered by my insurance?
  6. 6How should I share data with my care team?
  7. 7What should I do if one reading looks wrong or does not match how I feel?

Which option fits which person?

The right next step depends on your diabetes type, medicines, symptoms, budget, and goals. This table is not a diagnosis or prescription; it is a conversation guide for your clinician.

Your situationSensible next step to discussMain trade-off
You use insulin or have frequent lowsAsk about CGM plus a backup meterMore data and alerts, but higher cost and more setup
You have type 2 diabetes and need occasional checksAsk whether a basic meter is enoughLower cost, but fewer trend insights
You have prediabetes and want to learn food patternsAsk if short-term monitoring or lab follow-up makes sensePattern insight can help, but overchecking can create stress
You are changing diet, activity, or weight-loss treatmentAsk how often to check and who should review the dataReadings may shift as appetite and food intake change
You want a no-finger-prick optionAsk whether a CGM is appropriate and whether you still need a meterFewer finger pricks, but confirmation may still be needed

What changes over time when you start monitoring?

In the first few weeks, many people learn which readings are stable and which ones swing after meals, exercise, illness, or missed medication. Over months, your clinician may compare home patterns with A1C / HbA1c and adjust the plan if needed 2.

More data is not always better. If checking glucose leads to fear, skipped meals, or medication changes without guidance, that is a reason to pause and ask your care team for a clearer plan.

3-min quiz

Start with a clinician-reviewed plan

If weight and metabolic health are part of your goal, Chia can review your health history online and help determine whether a compounded GLP-1 option or a protocol such as Weight + Energy fits. A prescription requires a medical evaluation and is not guaranteed. Compounded medications and the Weight + Energy protocol are not FDA-approved.

References

  1. 1.U.S. Food and Drug Administration. Blood Glucose Monitoring Devices. FDA, 2026.
  2. 2.Mathew TK, Zubair M, Tadi P. Blood Glucose Monitoring. StatPearls. National Library of Medicine, 2026.
  3. 3.Maiorino MI, Signoriello S, Maio A, et al. A systematic review on clinical implication of continuous glucose monitoring in diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020.
  4. 4.Jangam S, Dunn T, Xu Y, et al. A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems on Glycemic Outcomes. Frontiers in Endocrinology, 2021.
  5. 5.National Library of Medicine. Studying the Effectiveness of Non-Invasive Glucose Monitoring. ClinicalTrials.gov identifier NCT02800044, 2016.
  6. 6.Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell, 2015.
  7. 7.Ben-Yacov O, Godneva A, Rein M, et al. Personalized Postprandial Glucose Response-Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes. Diabetes Care, 2021.
  8. 8.Shamanna P, Joshi S, Thajudeen M, et al. Personalized nutrition in type 2 diabetes remission: application of digital twin technology for predictive glycemic control. Frontiers in Endocrinology, 2024.
  9. 9.American Diabetes Association. Factors Affecting Blood Glucose. Diabetes.org, 2026.
  10. 10.Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care, 2016.
  11. 11.American Diabetes Association Professional Practice Committee. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2024. Diabetes Care, 2024.
  12. 12.Novo Nordisk. Prescribing Information for Wegovy, Ozempic, and Rybelsus (semaglutide), 2026.
  13. 13.Eli Lilly and Company. Prescribing Information for Zepbound and Mounjaro (tirzepatide), 2026.

About this article

Chia Health Editorial TeamEvidence-reviewed health education

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.

Get a personalized plan

See if GLP-1 is right for your body.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides